Lantheus calls time on me-too Pluvicto
Final survival analysis draws a blank, and Lantheus throws in the towel.
Amgen takes Imdelltra front line
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
Moderna returns to oncology
Three off-the-shelf mRNA therapies join intismeran autogene.
CDH17 becomes flavour of the month
Antibody-drug conjugates hitting this target abound.
Vepdegestrant’s promise narrows
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
